NeoAG Summit 2025: Induction of Neoantigen-Specific Immune Responses by VB10.NEO in Combination with Atezolizumab in Heavily Pretreated Patients with Advanced Solid Tumors; Final Analysis of the Phase 1b VB N-02 Trial